These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Termination of normal and pathological pregnancy with Sulprostone.
    Author: Fischer Z, Chwalisz K, Michałkiewicz W.
    Journal: Acta Chir Hung; 1986; 27(3):151-6. PubMed ID: 3825407.
    Abstract:
    262 patients with normal pregnancy in the first and second trimester and 55 patients with pathological pregnancy (missed abortion, intrauterine death of the foetus, molar pregnancy) were successfully treated with the PGE2 analogue Sulprostone (Schering A. G.). The drug was administered intramuscularly in the first trimester of normal and pathological pregnancy and by constant intravenous drop infusion for induction of abortion in the second and third trimesters of pregnancy. In case of 38 patients Sulprostone was injected intramural-cervically for cervical dilatation. The efficacy was high and the incidence of side-effects was low and more acceptable in all groups compared with that after natural prostaglandins. On the basis of the results presented, the authors recommend for pregnancy termination with Sulprostone the intramuscular route in the first trimester of normal and pathological pregnancy and intravenous infusion in the second and third trimesters. 262 patients with normal pregnancy in the 1st and 2nd trimester and 55 patients with pathological pregnancy (missed abortion, intrauterine death of the fetus, molar pregnancy) were treated with the prostaglandin E2 analogue Sulprostone to evaluate the safety, effectiveness, and acceptability of this drug to induce abortion in the 1st and 2nd trimesters of normal and pathological pregnancy as well as to dilate the cervix prior to surgical artificial abortion. The patients, ranging in age from 16-38 years, were admitted to the Institute of Obstetrics and Gynecology of the Medical Academy of Poznan, Poland. All patients volunteered to participate in this study. Among those patients admitted because of artificial abortion, duration of amenorrhea ranged from 6-12 weeks. The patients were divided into 3 groups. To the 23 patients in the 1st group, Sulprostone was given 2-3 times 500 mcg intramuscularly at 3-6 hour intervals to induce abortion. Curettage was performed after abortion or within 24 hours when abortion failed to occur. In the 2nd group of 10, Sulprostone was used for pharmacological cervix dilatation prior to curettage. 25 mcg of the drug was administered intramuscular-cervically to 32 patients 12 hours before surgical evacuation of cavum uteri. In 191 pregnancies Sulprostone was administered intramuscularly with 1 dose of 500 mcg also 12 hours prior to curettage. In the group of missed abortion (n = 23), 1-3 doses of 500 mcg were injected intramuscularly. In the case of 10 patients admitted for therapeutic abortion in the 2nd trimester group of intrauterine fetal death, a total dose of 1000-1500 mcg of Sulprostone was infused for over 12 hours. The incidence of gastrointestinal side effects in all groups was limited and clinically acceptable. In the case of induced uterine pains, the analgesic Dolantin was offered on an as-needed basis. Systemic side-effects requiring discontinuation of therapy with Sulprostone were not observed. The 262 patients with normal pregnancy and the 55 patients with pathological pregnancy were treated successfully with Sulprostone. The intramuscular administration seems to be preferable in the 1st trimester for cervical dilatation and other indications and intravenous infusion in the 2nd and 3rd trimesters.
    [Abstract] [Full Text] [Related] [New Search]